Scientific Program

12th International Conference on Cachexia, Sarcopenia & Muscle Wasting

Berlin, 06-08 Dec 2019 

Charite Umb logo

A
09:00 – 10:30 HALL B

Opening session

(talk 1 and 2: 20 minutes + 5 minutes discussion, talk 3 and 4: 14 minutes + 4 minutes discussion)

Chairs: Annemie Schols (The Netherlands) John Morley (USA)

09:00 – 09:04

Welcome

Stefan Anker (Germany)

  1. 09:04 – 09:24

“Prometheus” basic science key note lecture

Proteolysis in muscle wasting: past, present and future

Didier Attaix (France)

  1. 09:29 – 09:49

“Hippocrates” clinical science key note lecture

Why skeletal muscle matters in chronic heart failure

Andrew Coats (UK)

  1. 09:54 – 10:08

Recent facts & figures: cachexia & SCWD

Stefan Anker (Germany)

  1. 10:12 – 10:26

Recent facts & figures: sarcopenia & frailty (the JCSM lecture)

Stephan von Haehling (Germany)

10:30 – 11:00 Coffee Break

 

11:00 – 13:00 HALL B

Novel targets parade

(talk 1: 12 minutes + 4 minutes discussion, talk 2 to 8: 10 minutes + 3 minutes discussion)

Chairs: Samuel Breit (Australia) Hans Degens (UK)

Xiaonan Wang (USA)

  1. 11:00 – 11:12

State of the art lecture: therapeutic interventions targeting mitochondria – rationale & clinical results Michelangelo Mancuso (Italy)

  1. 11:16 – 11:26

Novel tumor-derived mediators of cachexia
Mauricio Berriel Diaz (Germany)

  1. 11.29 – 11:39

Metastasis and cancer cachexia

Swarnali Acharyya (USA)

  1. 11:42 – 11:52

Epi-genomics landscapes in cancer cachexia
Søren Fisker-Schmidt (Germany)

  1. 11:55 – 12:05

Mechanism of p300 activation and mediation of muscle wasting in cancer cachexia
Yi-Ping Li (USA)

  1. 12:08 – 12:18

Targeting the ubiquitin-proteasome system to counteract cancer cachexia – update 2019
Volker Adams (Germany)

  1. 12:21 – 12:31

Activating Mas receptor to reduce cachexia
Gordon Lynch (Australia)

  1. 12:34 – 12:44

Intervention strategies targeting Critical Illness Myopathy (CIM) and Ventilator Induced Diaphragm Dysfunction (VIDD) Lars Larsson (Sweden)

  1. 12:47 – 12:57

L-ornithine L-aspartate for the treatment of sarcopenia in liver cirrhosis
Roger Butterworth (Canada)

11:00 – 13:00 HALL A

Bone, muscle and appetite in cachexia and sarcopenia

(each talk: 8 minutes + 3 minutes discussion)

Chairs: Paola Costelli (Italy) Josep Argiles (Spain)

  1. 11:00 – 11:08

Musculoskeletal complications of cancer and its treatments
Andrea Bonetto (USA)

  1. 11:11 – 11:19

Muscle-bone crosstalk – results from the experimental studies
Robert Kob (Germany)

  1. 11:22 – 11:30

Bone-muscle crosstalk in bone metastatic cancer
David Waning (USA)

4: 11:33 – 11:41

Role of muscle and bone factors in energetics and metabolism Gustavo Duque (Australia)

  1. 11:44 – 11:52

The role of microRNA in osteosarcopenia
Hanna Taipaleenmäki (Germany)

  1. 11:55 – 12:03

Does testosterone play a key role in osteosarcopenia?
Giuseppe Rosano (UK)

  1. 12:06 – 12:14

Low muscle mass and strength as a risk factor for fracture – clinical studies Jürgen Bauer (Germany)

  1. 12:17 – 12:25

Impact of the fracture on muscle strength and physical performance Pawel Szulc (France)

  1. 12:28 – 12:36

Receptor-modified approach on anorexia-cachexia syndrome with an emphasis of ghrelin-neuropeptide Y-orexin hunger system

Yasuhito Uezono (Japan)

12:39 – 13:00

Panel discussion

 

 

13:15–14:15

Lunch Session of the Journal of Cachexia, Sarcopenia and Muscle (JCSM)

Chairs: Stefan Anker (Germany) Andrew Coats (UK)

JCSM and its daughter journals

Stephan von Haehling (Germany)

HALL B

 

Open Access publishing / Institutional publication funds / the Wiley DEAL for Germany

Jenny Delasalle (Germany)

Panel discussion DE

 

14:30 – 16:00 HALL B

Cachexia, sarcopenia and frailty in acute illness: clinical discussion

(each talk: 14 minutes + 4 minutes discussion)

Chairs: Bette Caan (USA)
Stephan von Haehling (Germany)

  1. 14:30 – 14:44

Assessing muscle and fat mass using imaging and biomarker tests in the critical ill: practical approach Emanuele Marzetti (Italy)

  1. 14:48 – 15:02

Critical-illness induced wasting of muscular fat tissue
Werner Z’Graggen (Switzerland)

  1. 15:06 – 15:20

Critical-illness acquired weakness (ICU-AW)
Tobias Wollersheim (Germany)

  1. 15:24 – 15:38

Outlook: additional critical illness induced neuromuscular dysfunctions Joerg Schefold (Switzerland)

  1. 15:42 – 15:56

Nutritional interventions in the ICU: an overview
Arthur van Zanten (The Netherlands)

16:00 – 17:00 Coffee break

14:30 – 16:00

Myogenesis for cachexia / sarcopenia

HALL A

 

(each talk: 14 minutes + 4 minutes discussion)

Chairs: Denis Guttridge (USA) James Carson (USA)

  1. 14:30 – 14:44

Mesoangioblast-driven muscle regeneration in aging
Maurilio Sampaolesi (Belgium)

  1. 14:48 – 15:02

Twist1, myogenesis and cancer cachexia
Azeddine Atfi (USA)

  1. 15:06 – 15:20

The S100B/RAGE pathway in myogenesis impairment Guglielmo Sorci (Italy)

  1. 15:24 – 15:38

Myoparr, a novel mediator of muscle wasting
Kunihiro Tsuchida (Japan)

  1. 15:42 – 15:56

The relevance of studying old vs young animals
Connie Jackaman (Australia)

 

 

16:05 – 16:55 POSTER AREA Poster Viewing 1
(each presentation: 2 minutes + 2 minutes discussion)

 

Poster Poster Poster Poster Poster Poster

16:10 – 16:50

session 1 1 session 1 2 session 1 3 session 1 4 session 1 5 session 1 6

Cachexia – mechanisms, animal models I (posters 1-11 to 1-18)

Chairs: Gordon Lynch, Jochen Springer

Cancer cachexia III (posters 3-24 to 3-29)

Chairs: Andrea Bonetto, Paola Costelli

Diagnosis of cachexia (posters 4-01 to 4-13)

Chairs: Vickie Baracos, Florian Strasser

Diagnosis of sarcopenia I (posters 5-01 to 5-12)

Chairs: Robert Mak, Angela Sanford

Muscle wasting & sarcopenia I (posters 6-01 to 6-11)

Chairs: Scott Brakenridge, Joseph Gordon

Therapeutic Development I (posters 9-01 to 9-10)

Chairs: Jose Garcia, Jennifer Le-Rademacher

 

Rapid Fire Abstracts Session 1

(each presentation: 3 minutes + 2 minutes discussion)

Chairs: Swarnali Acharyya (USA) Stephen Harridge (UK)

16:10 – 16:13

18F-FDG PET imaging in preclinical tumour-bearing mouse models of cachexia suggests that Fn14 plays a role in glycolytic changes in the tumour occurring during cancer cachexia (1-05)
Ingrid Burvenich (Australia)

16:15 – 16:18

Serological, morphological and molecular markers of denervation and NMJ degeneration underlie muscle wasting in human cancer cachexia (1-08)

Sandra Zampieri (Italy)

16:20 – 16:23

Exploring the contribution of the liver to cancer cachexia development (2-05)

Eveline Molocea (Germany)

16:25 – 16:28

Interleukin-6 controls microRNA-regulated networks in skeletal muscle cells (2-09)

Robson Carvalho (Brazil)

16:30 – 16:33

ZIP14 as a mediator of cachexia in metastatic cancers (2-14)

Anup Biswas (USA)

16:35 – 16:38

Inflammatory pathways involved in the gut-brain axis in cachexia (3-09)

Xiaolin Li (The Netherlands)

16:40 – 16:43

Lipocalin 2 is a driver of sickness response during pancreatic cancer cachexia (3-23)

Brennan Olson (USA)

HALL A

 

17:00 – 18:30 HALL B Cachexia in chronic illness: update 2019
(each talk: 14 minutes + 4 minutes discussion) Chairs: Kamyar Kalantar-Zadeh (USA)

Oliver Bathe (Canada)

  1. 17:00 – 17:14

Cachexia in chronic obstructive pulmonary disease
Annemie Schols (The Netherlands)

  1. 17:18 – 17:32

Cachexia and protein-energy wasting liver disease
Srinivasan Dasarathy (USA)

  1. 17:36 – 17:50

Diagnosis, treatment and prevention of cardiac cachexia in heart failure Stephan von Haehling (Germany)

  1. 17:54 – 18:08

Liver cachexia

Matthias Plauth (Germany)

  1. 18:12 – 18:26

Anorexia and cachexia
Maurizio Muscaritoli (Italy)

 

18:30 – 20:00

17:00 – 18:30 HALL A

Muscle stem cells and regeneration in sarcopenia and cachexia

(each talk: 14 minutes + 4 minutes discussion)

Chairs: David Glass (USA) Volker Adams (Germany)

  1. 17:00 – 17:14

Regulation of muscle stem cells and regeneration during aging in humans Abigail Mackey (Denmark)

  1. 17:18 – 17:32

Cross-talk between muscle stem cells, inflammation and fibrosis during muscle regeneration in aging Alessandra Sacco (USA)

  1. 17:36 – 17:50

Therapeutic interventions targeting cellular communication in the aged stem cell niche
Jerome Feige (Switzerland)

  1. 17:54 – 18:08

Myogenic commitment in cancer cachexia
Denis Guttridge (USA)

  1. 18:12 – 18:26

Cell therapy of muscle injuries: basic principles and new insights in mechanisms
Sven Geißler (Germany)

Wine & Cheese Welcome Reception in Poster Area

 

7

PROGRAM OVERVIEW, SATURDAY, DECEMBER 7, 2019

 

8:00 – 8:45
Breakfast Seminar Biomarkers in cachexia

Chairs: Stefan Anker (Germany) Giuseppe Rosano (UK)

Andrew Coats (UK)

Biomarkers for risk assessment in cachexia

Stephan von Haehling (Germany)

Biomarkers for muscle mass assessment in sarcopenia & cachexia

Emanuele Marzetti (Italy)

Cancer cachexia as cardiovascular disease: evidence from biomarker research

Markus Anker (Germany)

Supported by educational grant from Thermofisher

8:00 – 8:45

Ken Fearon Career Café – Meet the Mentor

Coordinated by:
Mitja Lainscak (Slovenia)

8:00 – 8:45
Statistical Seminar
An introduction to time-to-event (survival) analysis

Coordinated by:
Jennifer Le-Rademacher (USA) Ruta Brazauskas (USA)

HALL B

 

HALL II

HALL A

 

Time-to-event outcomes such as time from treatment to disease recurrence or time from diagnosis to death are common endpoints in biomedical research. These outcomes require that the study subjects be followed over time. In practice, it is not possible to follow all subjects until they experience the events of interest. The event times for subjects who are lost to follow-up before experiencing the events are not observed. These patients are censored at the time of their last follow-up. Time-to-event analysis (commonly called survival analysis) methods are needed in studies with time-to-event outcome to account for censoring. Due to the complexity of time-to-event methods, knowledge of the method assumptions and basic principles is important. Great care is needed when applying them in practice or interpreting published studies. In this seminar, we will

  • −  Introduce basic concepts of time-to-event data and explain the difference between various types of survival data including competing risks data
  • −  Introduce common analysis methods including the Kaplan-Meier estimator, the Cox proportional hazards model, the cumulative incidence function, and the Fine-Gray model; and
  • −  Provide practical guidance for analyzing time-to-event data.

8

HI

9:00 – 10:30 HALL B

Symptoms of patients with cachexia and their therapy

(each talk: 14 minutes + 4 minutes discussion)

Chairs: Aminah Jatoi (USA) Rainer Wirth (Germany)

  1. 09:00 – 09:14

Swallowing problems

Hidetaka Wakabayashi (Japan)

  1. 09:18 – 09:32

Pain

Florian Strasser (Switzerland)

  1. 09:36 – 09:50

Depression

Joanne Reid (UK)

  1. 09:54 – 10:08

Muscle weakness and fatigue: how to assess objectivity
Richard Dunne (USA)

  1. 10:12 – 10:26

Shortness of breath

Markus Anker (Germany)

9:00 – 10:30 HALL A

Mitochondria: a nexus for muscle wasting and impaired metabolism

(each talk: 14 minutes + 4 minutes discussion)

Chairs: Marco Sandri (Italy) Jochen Springer (Germany)

  1. 09:00 – 09:14

Mitochondrial dynamics in the regulation of muscle mass Antonio Zorzano (Spain)

  1. 09:18 – 09:32

Oxidative stress impact on muscle mass and function
Maria Carmen Gomez-Cabrera (Spain)

  1. 09:36 – 09:50

Feeding mitochondria to counteract cachexia
Klaske van Norren (The Netherlands)

  1. 09:54 – 10:08

Exercise and oxidative metabolism in muscle wasting
James Carson (USA)

  1. 10:12 – 10:26

Nix induced mitochondrial fission, mitophagy, and myocyte insulin resistance are abrogated by PKA phosphorylation

PROGRAM OVERVIEW, SATURDAY, DECEMBER 7, 2019

 

Joseph Gordon (Canada)

 

10:30 – 11:30

Coffee Break

 

10:35 – 11:30
Poster Viewing 2
(each presentation: 2 minutes + 2 minutes discussion)

POSTER AREA

 

Poster session 2 1 Poster session 2 2 Poster session 2 3 Poster session 2 4 Poster session 2 5 Poster session 2 6

Cachexia – mechanisms, animal models II (posters 1-01 to 1-10)

Chairs: Gordon Lynch, Jochen Springer

Cachexia – mechanisms, basic (posters 2-01 to 2-14)

Chairs: Yi-Ping Li, Fabio Penna

Cancer cachexia I (posters 3-01 to 3-12)

Chairs: Jeffrey Crawford, Stephan von Haehling

Muscle wasting & sarcopenia II (posters 6-12 to 6-22)

Chairs: Srinivasan Dasarathy, Wolfram Doehner

Nutrition and appetite II (posters 7-13 to 7-24)

Chairs: Akio Inui, Arthur van Zanten

Physical activity & training I (posters 8-01 to 8-11)

Chairs: Volker Adams, Mikel Izquidero

9

PROGRAM OVERVIEW, SATURDAY, DECEMBER 7, 2019

 

10:40 – 11:20

Rapid Fire Abstracts Session 2

(each presentation: 3 minutes + 2 minute discussion)

Chairs: Matthias Plauth (Germany) Toshihiko Yada (Japan)

10:40 – 10:43

HALL A

 

Dysregulation of small non-coding RNAs in the skeletal muscle and in plasma-derived microvesicles during experimental cancer cachexia (4-05)
Marc Beltra Bach (Italy)

10:45 – 10:48

NMJ failure in aged C57BL/6J mice: defining the timeline and investigating potential therapeutics (5-04)
David Arnold (USA)

10:50 – 10:53

GDF-15 circulating levels in cancer patients with anorexia and sarcopenia (5-19)

Alessio Molfino (Italy)

10:55 – 10:58

Low-magnitude, high-frequency vibration treatment attenuates age-related neuromuscular junction degeneration (5-24)
Simon Chow (China)

11:00 – 11:03

Biostatistical approaches for drug repositioning: NUDT3 & KLF5 for lean mass & HLA- DQB1-AS1 for hand grip skeletal muscles traits and their associated SNPs as candidate targets (6-01)
Abhishek Narain Singh (Finland)

11:05 – 11:08

Spsb1 is involved in inflammation-induced muscle atrophy (6-02)

Yi Li (Germany)

11:10 – 11:13

Muscle wasting in cancer involves suppression of ribosomal production and increased expression of the ribophagy receptor NUFIP1 (6-06)
Gustavo Nader (USA)

11:15 – 11:18

Skeletal muscle mTORC1 regulates neuromuscular junction stability (6-07)

Bert Blaauw (Italy)

10

PROGRAM OVERVIEW, SATURDAY, DECEMBER 7, 2019

 

JK

11:30 – 13:00 HALL B Sarcopenia and frailty in chronic illness
(each talk: 14 minutes + 4 minutes discussion) Chairs: Francesco Landi (Italy)

John Morley (USA)

  1. 11:30 – 11:44

Sarcopenia in chronic kidney disease and its therapy
Kamyar Kalantar-Zadeh (USA)

  1. 11:48 – 12:02

Sarcopenia in COPD and its therapy

Ramon Langen (The Netherlands)

  1. 12:06 – 12:20

Heart failure sarcopenia and adiposity paradox
Mitja Lainscak (Slovenia)

  1. 12:24 – 12:38

Heart Failure Association / European Society of Cardiology position paper on frailty in patients with heart failure Cristiana Vitale (Italy)

  1. 12:42 – 12:56

Adipose tissue browning and vitamin D in chronic illness
Robert Mak (USA)

13:15 – 14:15

Lunch Seminar Session on Cachexia Research sponsored by

Session on Cachexia Research

Chairs: Bei Zhang (USA)
Stefan Anker (Germany)

Introduction: cachexia unmet needs, opportunities and challenges

Bei Zhang (USA)

Overview of research in cachexia
Cancer cachexia focus : HT1080 tumor cachexia model for preclinical research
Danna Breen (USA)

Non-cancer cachexia focus: preclinical models for non-cancer related cachectic and wasting conditions
Zhidan Wu (USA)

Wrap up: where do we go from here

Stefan Anker (Germany)

In collaboration with Pfizer

11:30 – 13:00 HALL A

Cachexia, sarcopenia and frailty in acute illness: from mechanisms to therapy

(each talk: 12 minutes + 3 minutes discussion)

Chairs: Maurilio Sampaolesi (Belgium) Tobias Wollersheim (Germany)

  1. 11:30 – 11:42

Satellite cells, inflammation and senescence
Stephen Harridge (UK)

  1. 11:45 – 11:57

The inflammatory “genomic storm” post trauma and sepsis – a driver of rapid muscle wasting
Scott Brakenridge (USA)

  1. 12:00 – 12:12

Age-related signaling and expression changes that may contribute to sarcopenia
David Glass (USA)

  1. 12:15 – 12:27

Post-sepsis microenvironment alterations in wasting muscle and adipose tissue
Jason Doles (USA)

  1. 12:30 – 12:42

Electrical stimulation as an intervention in the critically ill
Steffen Weber-Carstens (Germany)

  1. 12:45 – 12:57

Potential nutritional interventions to prevent acute muscle wasting Alessandro Laviano (Italy)

 

HALL B

 

11

PROGRAM OVERVIEW, SATURDAY, DECEMBER 7, 2019

 

LM

14:30 – 16:15 HALL B

Late breaking clinical science and clinical trial update

(each talk: 10 minutes + 5 minutes discussion)

Chairs: Stefan Anker (Germany) Andrew Coats (UK)

Marina Zemskova (USA)

  1. 14:30 – 14:40

The EFFORT study – effective to preserve muscle mass and functional outcomes in critically ill patients Christian Stoppe (Germany)

  1. 14:45 – 14:55

Endocrine manipulation of cachexia in mice with lung cancer
Marcus DaSilva Goncalves (USA)

  1. 15:00 – 15:10

Beyond ROMANA: moving forward with the anamorelin phase 3 SCALA program
Ruben Giorgino (Switzerland)

  1. 15:15 – 15:25

Iodide reduces cachexia in a BALB/c CT26 mouse tumor model
Michael Insko (USA)

  1. 15:30 – 15:40

Effect of Elamipretide on exercise, muscle strength, and heart function in patients with Barth Syndrome after 48 weeks of therapy
Jim Carr (USA)

  1. 15:45 – 15:55

SARA program: preliminary findings from SARA-OBS study and impacts on the SARA-INT study design
Samuel Agus (USA)

16:00 – 16:15

Panel discussion

16:00 – 17:00 Coffee break

14:30 – 16:00 HALL A

Sarcopenia and aging – diagnosis, exercise, nutrition

(each talk: 14 minutes + 4 minutes discussion)

Chairs: Vickie Baracos (Canada) Wolfram Doehner (Germany)

  1. 14:30 – 14:44

The SCWD consensus on sarcopenia

John Morley (USA)

  1. 14:48 – 15:02

Screening for sarcopenia

Angela Sanford (USA)

  1. 15:06 – 15:20

Exercise as a treatment of frailty in hospital care
Mikel Izquierdo (Spain)

  1. 15:24 – 15:38

Treating sarcopenia in a rural community
Janice Lundy (USA)

  1. 15:42 – 15:56

Herbal medicine based nutrition

Akio Inui (Japan)

 

12

16:05 – 16:55
Poster Viewing 3
(each presentation: 2 minutes + 2 minutes discussion)

POSTER AREA

PROGRAM OVERVIEW, SATURDAY, DECEMBER 7, 2019

 

Poster Poster Poster Poster Poster

16:10 – 16:50

session 3 1 session 3 2 session 3 3 session 3 4 session 3 5

Therapeutic development II (posters 9-11 to 9-17)

Chairs: Jose Garcia, Jennifer Le-Rademacher

Cancer cachexia II (posters 3-13 to 3-23)

Chairs: Andrea Bonetto, Paola Costelli

Diagnosis of sarcopenia III (posters 5-23 to 5-32)

Chairs: Mauricio Berriel-Diaz , Ramon Langen

Muscle wasting & sarcopenia III (posters 6-23 to 6-33)

Chairs: Maurilio Sampaolesi, David Waning

Physical activity & training II (posters 8-12 to 8-22)

Chairs: Bette Caan, James Carson

 

Rapid Fire Abstracts Session 3

(each presentation: 3 minutes + 2 minutes discussion)

Chairs: Connie Jackaman (Australia) Francesco Landi (Italy)

16:10 – 16:13

SRF role as a mechano-transductor in response to exercise in cancer cachexia (3-10)

Medhi Hassani (Italy)

16:15 – 16:18

Fried frailty phenotype and hand grip strength in advanced cancer patients (6-38)

Pia Weinlaender (Germany)

16:20 – 16:23

Association of growth differentiation factor 15 and malnutrition inflammation score in a prospective hemodialysis cohort (7-04)
Connie Rhee (USA)

16:25 – 16:28

Tele-rehabilitation to prevent sarcopenia and disability in advanced cancer: a randomized controlled trial (8-07)
Andrea Cheville (USA)

16:30 – 16:33

Anaerobic threshold-based exercise training program stimulates genes that control skeletal muscle differentiation and function in heart failure patients (8-10)
Renata Dmitrieva (Russia)

16:35 – 16:38

Myosin activity triggers muscle growth through a novel mechanotransduction signalling pathway involving Forcin (8-11)
Simon Hughes (UK)

16:40 – 16:43

Serum Amyloid A1 mediates myotube atrophy via Toll-like receptors (9-07)

Melanie Kny (Germany)

16:45 – 16:48

Safety and efficacy of bimagrumab in community-dwelling older adults with sarcopenia (9-10)
Didier Laurent (USA)

HALL A

 

13

PROGRAM OVERVIEW, SATURDAY, DECEMBER 7, 2019

 

NO

17:00 – 19:00 HALL B Hot topic in muscle wasting
(each talk: 8 minutes + 4 minutes discussion)

Chairs: Jochen Springer (Germany) Xiaonan Wang (USA)

Antonio Zorzano (Spain)

  1. 17:00 – 17:08

Molecular mechanisms and promising therapies in muscle wasting
Amanda Vest (USA)

  1. 17:12 – 17:20

Mytho a novel player in autophagy and cancer
Marco Sandri (Italy)

  1. 17:24 – 17:32

Key facilitator proteins that mediate sarcolemma membrane repair have potential as therapeutics for muscle disease and injury

Noah Weisleder (USA)

  1. 17:36 – 17:44

Role of the microcirculation in muscle wasting and plasticity
Hans Degens (UK)

  1. 17:48 – 17:56

Tissue sodium accumulation and peripheral insulin sensitivity in maintenance hemodialysis patients Talat Alp Ikizler (USA)

  1. 18:00 – 18:08

Apelin and sarcopenia of aging

Cédric Dray (France)

  1. 18:12 – 18:20

Deacetylase inhibitors to treat muscle wasting
Vered Raz (The Netherlands)

  1. 18:24 – 18:32

An update on the role of anabolic steroids in muscle wasting Jeffrey Crawford (USA)

18:36 – 19.00

Panel discussion

17:00 – 19:00 HALL A The fat and appetite session
(each talk: 8 minutes + 4 minutes discussion) Chairs: Stephan Herzig (Germany)

Klaske van Norren (The Netherlands)

  1. 17:00 – 17:08

An update on brown fat

Josep Argiles (Spain)

  1. 17:12 – 17:20

Brown fat and cancer
cachexia: understanding interactive mechanisms
Annemie Schols (The Netherlands)

  1. 17:24 – 17:32

Measuring brown fat in humans

Jan Nedergaard (Sweden)

  1. 17:36 – 17:44

TLR4 involvement in adipose tissue loss in cancer cachexia
Miguel L. Batista (Brazil)

  1. 17:48 – 17:56

A novel cancer variant discovered by identifying tumor-driven changes in fat redistribution
Oliver Bathe (Canada)

  1. 18:00 – 18:08

The clinical impact and spectrum of obesity and cancer
Aminah Jatoi (USA)

  1. 18:12 – 18:20

The gap between existing large population data and the need of novel database relevant to cachexia
Melissa Miller (USA)

  1. 18:24 – 18:32

In-vivo screening platform to identify new pro-cachectic / anorectic tumor factors
Olivier Bezy (USA)

18:36 – 19:00

Panel discussion

 

14

07:30 – 8:15

Ken Fearon Career Café – Meet the Mentor

Coordinated by:
Mitja Lainscak (Slovenia)

07:30 – 8:15
Statistical Seminar
An introduction to time-to-event (survival) analysis

Coordinated by:
Jennifer Le-Rademacher (USA) Ruta Brazauskas (USA)

HALL II

HALL A

PROGRAM OVERVIEW, SUNDAY, DECEMBER 8, 2019

 

Time-to-event outcomes such as time from treatment to disease recurrence or time from diagnosis to death are common endpoints in biomedical research. These outcomes require that the study subjects be followed over time. In practice, it is not possible to follow all subjects until they experience the events of interest. The event times for subjects who are lost to follow-up before experiencing the events are not observed. These patients are censored at the time of their last follow-up. Time-to-event analysis (commonly called survival analysis) methods are needed in studies with time-to-event outcome to account for censoring. Due to the complexity of time-to-event methods, knowledge of the method assumptions and basic principles is important. Great care is needed when applying them in practice or interpreting published studies. In this seminar, we will

  • −  Introduce basic concepts of time-to-event data and explain the difference between various types of survival data including competing risks data
  • −  Introduce common analysis methods including the Kaplan-Meier estimator, the Cox proportional hazards model, the cumulative incidence function, and the Fine-Gray model; and

− Provide practical guidance for analyzing time-to-event data.

P
08:30 – 10:00

Neurological impact of sarcopenia

(each talk: 14 minutes + 4 minutes discussion)

Chairs: Akio Inui (Japan)
Sein Schmidt (Germany)

  1. 08:30 – 08:44

Neurophysiological basis of anorexia-cachexia syndrome

Toshihiko Yada (Japan)

  1. 08:48 – 09:02

Sarcopenia in neuromuscular diseases

Gabriele Siciliano (Italy)

  1. 09:06 – 09:20

Stroke and sarcopenia

Wolfram Doehner (Germany)

  1. 09:24 – 09:38

Dementia and sarcopenia A vicious circle

Rainer Wirth (Germany)

  1. 09:42 – 09:56

Brain wasting

Matthias Endres (Germany)

HALL B

 

15

PROGRAM OVERVIEW, SUNDAY, DECEMBER 8, 2019

 

Q
8:30 – 10:00

Young investigators awards session

(each talk: 10 minutes + 5 minutes discussion)

Judges:Volker Adams (Germany) Vickie Baracos (Canada)

Bette Caan (USA)
Paola Costelli (Italy)
Steven Heymsfield (USA) Jalid Sehouli (Germany) Florian Strasser (Switzerland)

Basic

8:30 – 8:40

HALL A

 

Cachexia induced by non-bone metastatic cancers is accompanied by bone, cartilage and bone marrow destruction (2-04)
Fabrizio Pin (USA)

8:45 – 8:55

Exercise preconditioning diminishes solute carrier protein expression and doxorubicin accumulation in the diaphragm (8-02)
Ashley Smuder (USA)

9:00 – 9:10

Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction (9-06)
Thomas Kunzke (Germany)

Clinical

9:15 – 9:25

Tumor organoids as a novel model to study cancer-induced cachexia in pancreatic cancer (2-08)
Rianne Vaes (The Netherlands)

9:30 – 9:40

Adverse muscle composition within obesity is associated with low functional performance and increased comorbidity – results from the large UK Biobank imaging study (5-05)
Jennifer Linge (Sweden)

9:45 – 9:55

Effects of exercise and beta-hydroxy-beta-methylbutyrate supplements on muscle mass, muscle strength, and physical performance in older women with muscle atrophy: a randomized, double-blind, placebo-controlled trial (9-01)
Yosuke Osuka (Japan)

10:00 – 11:00 Coffee break

 

16

PROGRAM OVERVIEW, SUNDAY, DECEMBER 8, 2019

 

10:05 – 10:55
Poster Viewing 4
(each presentation: 2 minutes + 2 minutes discussion)

POSTER AREA

Poster session 4 1 Poster session 4 2 Poster session 4 3 Poster session 4 4

Diagnosis of sarcopenia II (posters 5-13 to 5-22)

Chairs: Robert Mak, Angela Sanford

Diagnosis of sarcopenia IV (posters 5-33 to 5-38)

Chairs: Mauricio Berriel-Diaz, Ramon Langen

Muscle wasting & sarcopenia IV (posters 6-34 to 6-41)

Chairs: Maurilio Sampaolesi, David Waning

Nutrition and appetite I (posters 7-01 to 7-12)

Chairs: Olivier Bezy, Klaske van Norren

RS

11:00 – 12:30 HALL B Sex matters in cachexia
(each talk: 14 minutes + 4 minutes discussion) Chairs: Yi-Ping Li (USA)

Filippo Rossi-Fanelli (Italy)

  1. 11:00 – 11:14

Multi-platform omics analyses document distinct phenotypes and mechanisms in cancer cachexia Vickie Baracos (Canada)

  1. 11:18 – 11:32

Sex-specific differences in treatment response in cancer cachexia
Jose Garcia (USA)

  1. 11:36 – 11:50

Sex specific phenotypes, mechanisms, and treatment response in mice and humans with pancreatic cancer Xiaoling Zhong (USA)

  1. 11:54 – 12:08

Sex differences in imaging for cachexia

Steven Heymsfield (USA)

5 12:12 – 12:26

The role of estrogen in cachexia- induced metabolic disruptions James Carson (USA)

12:30 – 13:00 Lunch break

11:00 – 12:30

HALL A

Cancer- and chemotherapy-induced wasting

(each talk: 14 minutes + 4 minutes discussion)

Chairs: Jeffrey Crawford (USA) Maurizio Muscaritoli (Italy)

  1. 11:00 – 11:14

Chemotherapy-induced metabolic abnormalities in cancer cachexia Thomas O’Connell (USA)

  1. 11:18 – 11:32

Skeletal muscle adaptations to chemotherapy and the protective effects of exercise
Michael Toth (USA)

  1. 11:36 – 11:50

Effects of Activin inhibition on chemotherapy-induced cachexia Juha Hulmi (Finland)

  1. 11:54 – 12:08

Chemotherapy to delay / counteract cachexia
Fabio Penna (Italy)

  1. 12:12 – 12:26

Multi-organ contributions to cancer cachexia
Stephan Herzig (Germany)

17

PROGRAM OVERVIEW, SUNDAY, DECEMBER 8, 2019

T
13:00 – 13:45

Frailty and sarcopenia

(each talk: 12 minutes + 3 minutes discussion)

Chairs: Jürgen Bauer (Germany) Florian Strasser (Switzerland)

  1. 13:00 – 13:12

Characterisation of the frail geriatric patient

Francesco Landi (Italy)

  1. 13:15 – 13:27

Exercise to improve muscle health and cancer outcomes

Bette Caan (USA)

  1. 13:30 – 13:42

Nutritional interventions: what is the evidence?

Mitja Lainscak (Slovenia)

U
13:45 – 15:15

Novel ideas to enhance muscle mass and function

(each talk: 12 minutes + 3 minutes discussion)

Chairs: Maria Carmen Gomez-Cabrera (Spain) Richard Dunne (USA)

  1. 13:45 – 13:57

Targeting the GDF15/MIC-1 pathway for anorexia / cachexia

Samuel Breit (Australia)

  1. 14:00 – 14:12

Satellite cells, muscle regeneration, and cancer cachexia

Jason Doles (USA)

  1. 14:15 – 14:27

CD8 T cells – a novel player in cachexia during viral infection

Andreas Bergthaler (Austria)

  1. 14:30 – 14:42

Making patients fat again: good idea? If so, how?

Andrew Coats (UK)

  1. 14:45 – 14:57

Data-driven identification and optimization of new medicines for cancer cachexia

Ben Zeskind (USA)

  1. 15:00 – 15:12

The HIPGEN Study – Allogeneic cell therapy for muscle injury in phase III

Tobias Winkler (Germany)

HALL B

HALL B

18

V
15:15 – 16:00

Highlights session

Chairs: Stefan Anker (Germany) Mitja Lainscak (Slovenia)

  1. 15:15 – 15:25

Basic science

Olivier Bezy (USA)

  1. 15:25 – 15:35

Clinical science & biomarkers

Stephan von Haehling (Germany)

  1. 15:35 – 15:45

Treatment & nutrition

Andrew Coats (UK)

Poster Awards
Young Investigator Awards Farewell

HALL B

PROGRAM OVERVIEW, SUNDAY, DECEMBER 8, 2019

19